Summit Highlights Discovery of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018

NEXT STORY
Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
PREV STORY
Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update

author_avatar
NASDAQ Market News

Cellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance

MADISON, Wis., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (“the company”), ...

author_avatar
NASDAQ Market News

Immunovaccine Announces Year-End 2017 Financial Results

HALIFAX, Nova Scotia, March 20, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a ...

author_avatar
NASDAQ Market News